Skip to main content

Remarkable Science.
Enduring Performance.

Remarkable Science.
Enduring Performance.

Remarkable Science.
Enduring Performance.

Remarkable Science.
Enduring Performance.

Remarkable Science.
Enduring Performance.

Remarkable Science.
Enduring Performance.

Remarkable Science.
Enduring Performance.

Aesthetics Pipeline

Revance will initially address Glabellar (frown) lines, one of the single greatest demands within the facial aesthetics category.
 

View Product Pipeline >>

Therapeutics Pipeline

Therapeutic indications for botulinum toxin represent more than half of the estimated $3.4 billion global neuromodulator market.
 

View Product Pipeline >>

DaxibotulinumtoxinA for Injection (RT002)

With investigational product candidate RT002 injectable, daxibotulinumtoxinA may result in an extended duration of response.
 
 

Learn More >>

Stock Quote

32.15  +3.06 (0.00%)

NASDAQ: RVNC - Dec 14 4:00 PM EST
 

Learn More >>

RT002 injectable and topical formulations are investigational product candidates. RT002 is currently undergoing clinical studies for both therapeutic and aesthetic indications.